ArticleFrontiers in oncology2026
Therapeutic efficacy of hispidulin-loaded carboxymethyl cellulose nanoparticles against mammary carcinogenesis through ROS-mediated apoptosis and tissue remodelling.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the apoptosis-modulating and therapeutic efficacy of hispidulin-loaded carboxymethyl cellulose nanoparticles (HIS-CMC NPs) in mammary carcinogenesis through Methods: Apoptotic activity of HIS-CMC NPs was assessed in MCF-7 cells using cell viability, intracellular reactive oxygen species (ROS), DAPI, acridine orange/ethidium bromide (AO/EB), and Annexin-V/PI flow cytometry assays. Therapeutic efficacy was further examined in a DMBA-induced mammary carcinogenesis BALB/c mice model through haematological, biochemical, histopathological, immunohistochemical and oxidative stress analyses. Results: HIS-CMC NPs significantly reduced MCF-7 cell viability and exhibited a lower IC Conclusions: HIS-CMC NPs effectively promoted ROS-dependent apoptosis and attenuated oxidative stress in mammary carcinogenesis. The nanoformulation demonstrated enhanced therapeutic efficacy with reduced systemic toxicity, highlighting its potential as a promising nanotherapeutic strategy for breast cancer management. HIS-CMC NPs, mammary carcinogenesis, apoptosis, oxidative stress, proliferation biomarkers, immunohistochemistry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.